
Marc-Oliver Grimm, MD, discusses a post-hoc analysis of the ARASENS trial in metastatic hormone-sensitive prostate cancer.

Your AI-Trained Oncology Knowledge Connection!


Marc-Oliver Grimm, MD, discusses a post-hoc analysis of the ARASENS trial in metastatic hormone-sensitive prostate cancer.

Marc-Oliver Grimm, MD discusses the clinical implications, short comings, and future steps following a post-hoc analysis from the phase 3 ARASENS trial.

Marc-Oliver Grimm, MD discusses darolutamide in combination with androgen deprivation therapy and docetaxel in mHSPC.